Novartis says Glivec misses main goal in study (Reuters)

- Novartis AG's carcinoma remedy Glivec fruitless to right its primary rationale newest a late-stage scan of patients extra enduring myeloid leukemia (CML), the Swiss drugmaker put into words possible Friday.